Seeking Alpha

Shares of Regeneron (REGN +10.1%) roar out of the gate after the company beats the estimate of...

Shares of Regeneron (REGN +10.1%) roar out of the gate after the company beats the estimate of analysts with its Q4 report and boosts its outlook for 2012 sales on its eye drug Eylea. The news could tip off weaker sales for Roche's (RHHBY.PK) Lucentis treatment - Regeneron's main rival in the space.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|